自身免疫性肝病精准诊治与临床转化研究的思考*

doi:10.3969/j.issn.1672-5069.2021.04.001

Abstract

Wang Qixia, Ma Xiong. Insights to precision medicine and clinical translational research in patients with autoimmune liver diseases[J]. Journal of Practical Hepatology, 2021, 24(4): 457-459.

[1] 马雄,王绮夏.自身免疫性肝病的研究现状.中华传染病杂志,2020,38(8):465-467.
[2] 王绮夏,马雄.免疫球蛋白G4相关肝胆疾病研究现状与挑战.中华肝脏病杂志,2018,26(6):401-403.
[3] Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology, 2020,72(2):671-722.
[4] Wei Y, Li Y, Yan L, et al. Alterations of gut microbiome in autoimmune hepatitis. Gut, 2020,69(3):569-577.
[5] You Z, Li Y, Wang Q, et al. The clinical significance of hepatic CD69⁺CD103⁺CD8⁺ resident memory T cells in autoimmune hepatitis. Hepatology, 2021[ahead of print].
[6] Lleo A, Leung PSC, Hirschfield GM, et al. The pathogenesis of primary biliary cholangitis: A comprehensive review.Semin Liver Dis,2020,40(1):34-48.
[7] Sun C, Xiao X, Yan L,et al. Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase: Is alkaline phosphatase truly a surrogate marker? J Autoimmun, 2019,99:33-38.
[8] Zhang H, Lian M, Zhang J, et a. The functional characteristics CCNI modulation of myeloid derived suppressor cells in liver inflammation. Hepatology, 2018, 67(1): 232-246.
[9] Tang R, Wei Y, Li Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut, 2018,67(3):534-541.
[10] Song J, Li Y, Bowlus CL, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis (PSC): a comprehensive review.Clin Rev Allergy Immunol, 2020,58(1):134-149.
[11] Ali AH, Bi Y, Machicado JD, et al. The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience.J Gastroenterol, 2020,55(11):1087-1097.

[1]	Li Bianli, Xu Lihong. Differential diagnosis of drug-induced liver injury, drug-induced autoimmune hepatitis and autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(4): 460-463.
[2]	Liang Yuping, Su Quanqiu, Zhang Hui, et al. Serum vitamin D deficiency in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(4): 464-467.
[3]	Liu Na, Zhang Huamin, Deng Qiaojuan. Impact of inhibition of TRAF6 gene expression on hepatic NF-κB-related protein expression in rats with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(4): 468-471.
[4]	Qi Mei, Zhang Ruijin, Tian Shuping, et al. Impacting factors in response to immunosuppressive therapy in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(3): 371-374.
[5]	Zhang Xinhe, Tian Haoyu, Li Yiling. Current therapeutic strategy for patients with primary biliary cholangitis [J]. Journal of Practical Hepatology, 2021, 24(3): 453-456.
[6]	Nie Liu, Peng Hanming, Liao Dongliang. Combination of ursodeoxycholic acid and prednisone and azathioprine in the treatment of patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(2): 224-227.
[7]	Li Qingling, He Shuguang, Yi Xiaoming, et al. Changes of peripheral blood lymphocyte PD-1 and PD-L1 expression in patients with autoimmune hepatitis receiving tripterygium wilfordii polyglycosides and magnesium iso-glycyrrhizate [J]. Journal of Practical Hepatology, 2021, 24(1): 79-82.
[8]	Wang Yu, Wang Nan, Wang Qiaoxia, et al. Liganlong and magnesium isoglycyrrhizate combination mitigates liver injury via inhibiting humoral immunity in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2020, 23(6): 821-824.
[9]	Ling Jing, Zhang Youjian, Song Xiongfeng. Changes of serum chemokines and GP73levels in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2020, 23(6): 825-828.
[10]	Zhang Jianrong, Gu Erli, Wang Zhongcheng, et al. Comparison of clinical characteristics of patients with autoimmune hepatitis, primary biliary cholangitis and AIH/PBC overlap syndrome [J]. Journal of Practical Hepatology, 2020, 23(6): 829-832.
[11]	Zhang Wei, Shi Junping. A new model for prevention and treatment of MAFLD to promote whole process stratification management [J]. Journal of Practical Hepatology, 2020, 23(5): 609-611.
[12]	Li Junying, Zhou Ling, Chen Jinjun. Surveillance and management of individuals with high risk of NAFLD [J]. Journal of Practical Hepatology, 2020, 23(5): 612-614.
[13]	Kong Ming, Duan Zhongping, Chen Yu. Focus on nutrition in patients with chronic liver disease [J]. Journal of Practical Hepatology, 2020, 23(4): 459-461.
[14]	Wen Qionghua, Tang Minyun, Wei Yu, et al. Auxiliary diagnostic value of serum adenosine deaminase and amyloid A protein in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2020, 23(4): 508-511.
[15]	Cheng Yuan, Zhang Yang, Mao Haizhou, et al. Diagnostic value of serum anti-tenoxalate hydrase antibody in patients with AIH [J]. Journal of Practical Hepatology, 2020, 23(4): 512-515.

Insights to precision medicine and clinical translational research in patients with autoimmune liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments